Astra Plots Post-Covid Future With $39 Billion Alexion Deal

...ighted where its growth will come from after the pandemic with a $39 billion deal for rare-disease specialist Alexion Pharmaceuticals Inc. Load Error The proposed cash-and-stock acquisition will add treatments for uncomm...
Read Full Article